Bavarian Nordic initiates phase II trial for Covid-19 vaccine

In a long-awaited phase II trial, Bavarian Nordic starts testing the efficacy of its Covid-19 vaccine for reinforcing existing immunity in persons either previously vaccinated or infected.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL TF

After having recently published promising data for its ABNCoV2 vaccine against Covid-19, Bavarian Nordic now begins a phase II trial for its candidate, Bavarian informs in a press release Monday morning.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading